Marshall Wace
CMMB

Marshall Wace’s Chemomab Therapeutics CMMB Stock Holding History

Marshall Wace’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,889
Closed -$1.21M – 3064
2021
Q2 		$1.21M Buy
+15,889
New +$1.55M 0.01% 1719

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
YAVAPFMC
Yahav Achim Ve Achayot - Provident Funds Management Company Tel-Aviv, Israel $144M AUM 82.62% 1-Year Est. Return

Marshall Wace's CMMB Position: Q3 2021 in Review

Marshall Wace sold out of Chemomab Therapeutics (CMMB) in Q3 2021, closing a stake of 15,889 shares — an estimated $1.21M sold.

Marshall Wace first reported a position in CMMB in Q2 2021 and held it in 1 quarter. The position peaked at $1.21M in Q2 2021. 15 funds tracked by Wall St. Rank hold CMMB as of Q3 2021.

  • Marshall Wace reported no remaining Chemomab Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace sold 15,889 Chemomab Therapeutics shares in Q3 2021, an estimated $1.21M.
  • Marshall Wace first reported a position in Chemomab Therapeutics in Q2 2021 and held it in 1 quarter.
  • Marshall Wace's Chemomab Therapeutics position peaked at $1.21M in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2021.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.